JP2022505094A5 - - Google Patents

Info

Publication number
JP2022505094A5
JP2022505094A5 JP2021521000A JP2021521000A JP2022505094A5 JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5 JP 2021521000 A JP2021521000 A JP 2021521000A JP 2021521000 A JP2021521000 A JP 2021521000A JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5
Authority
JP
Japan
Prior art keywords
residue
complex
sequence
numbered
relation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505094A (ja
JP7584405B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/058777 external-priority patent/WO2020079586A1/en
Publication of JP2022505094A publication Critical patent/JP2022505094A/ja
Publication of JP2022505094A5 publication Critical patent/JP2022505094A5/ja
Application granted granted Critical
Publication of JP7584405B2 publication Critical patent/JP7584405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521000A 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 Active JP7584405B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
US62/746,804 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (3)

Publication Number Publication Date
JP2022505094A JP2022505094A (ja) 2022-01-14
JP2022505094A5 true JP2022505094A5 (https=) 2022-10-31
JP7584405B2 JP7584405B2 (ja) 2024-11-15

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521000A Active JP7584405B2 (ja) 2018-10-17 2019-10-15 改変されたサイトメガロウイルスタンパク質及び安定化された複合体

Country Status (8)

Country Link
US (2) US11932669B2 (https=)
EP (1) EP3866845A1 (https=)
JP (1) JP7584405B2 (https=)
CN (1) CN113271968B (https=)
BR (1) BR112021006812A2 (https=)
CA (1) CA3116175A1 (https=)
MX (1) MX2021004273A (https=)
WO (1) WO2020079586A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
EP4526327A1 (en) * 2022-05-20 2025-03-26 GlaxoSmithKline Biologicals S.A. Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388186A1 (en) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company External regulation of gene expression
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
HK1046911A1 (zh) 1999-06-25 2003-01-30 Progenics Pharmaceuticals, Inc. 经稳定的病毒外膜蛋白质及其使用
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
EP2320945A4 (en) 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE MILZBRANDIMPFSTOFFFORMULIERUNGEN
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CA2885145A1 (en) 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
MX2016014660A (es) 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
WO2015181142A1 (en) * 2014-05-27 2015-12-03 Glaxosmithkline Biologicals S.A. Cytomegalovirus complexes and uses thereof
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3600397A4 (en) * 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES

Similar Documents

Publication Publication Date Title
EP3319633B1 (en) Vaccine against rsv
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
JP2022505094A5 (https=)
FI3256579T3 (fi) Kysteiiniproteaasi
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
JP2018510622A5 (https=)
FI3247722T3 (fi) Sytomegalovirusantigeenejä ja niiden käyttöjä
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
HRP20190970T1 (hr) Polipeptidi koji sadrže neglikozilirani fc
FI3393512T3 (fi) Rsv f -proteiinin mutantteja
MY150105A (en) A novel surface exposed haemophilus influenzae protein (protein e; pe)
JP2018528237A5 (https=)
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
JP2010504096A5 (https=)
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
RU2020116307A (ru) Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса
BR112015032556A2 (pt) Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo
FI2956471T3 (fi) Il-1-beetan estäjän koostumus ja sen käyttö
JP2020518249A5 (https=)
RU2014144881A (ru) Способ экспрессии полипептидов с применением модифицированных нуклеиновых кислот
PE20020857A1 (es) Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras
JP2013523084A5 (https=)
JP2015529219A5 (https=)